Russia approves clinical trials for Chinese COVID-19 vaccine Ad5-Ncov: Ifax

Reuters , Monday 7 Dec 2020

Ad5-nCoV is a vaccine candidate co-developed by CanSino Biologics and a Chinese military-backed research unit

Russia has granted approval for clinical trials to be held for the Chinese COVID-19 vaccine Ad5-Ncov involving 8,000 volunteers, the Interfax news agency reported on Monday.

Ad5-nCoV is a vaccine candidate co-developed by CanSino Biologics and a Chinese military-backed research unit.

Short link: